Status:
COMPLETED
Chemotherapy and Radiation Following Pancreatic Surgery
Lead Sponsor:
Washington University School of Medicine
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by g...
Detailed Description
The adjuvant therapy of pancreas cancer has remained a challenge for oncology specialists from all disciplines since the initial development of the pancreaticoduodenectomy by Whipple in 1935 (Whipple,...
Eligibility Criteria
Inclusion
- Resected adenocarcinoma of the pancreas
- ECOG performance status 0 or 1
- No prior chemotherapy or radiation therapy for cancer within the last five years.
- Prior history of other malignancies allowable, if stable or requiring no active therapy.
- Absolute neutrophil count \>/= 1,500/mm3, platelet count \>/= 100,000/mm3, and hemoglobin \>/= 9 g/dL.
- Serum creatinine \</= 2 mg/dL.
- Serum bilirubin \</= 3.0 mg/dL.
- Serum transaminases ( SGOT and SGPT) \</= 5-fold the institutional upper limits.
- No co-existing severe medical illnesses, such as unstable angina, uncontrolled diabetes mellitus, uncontrolled arrhythmia or uncontrolled infection.
- Able to sign an informed consent.
Exclusion
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00660270
Start Date
May 1 2002
End Date
February 1 2009
Last Update
April 23 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63119